Optimal Antiplatelet Therapy: Duration of Antiplatelet Therapy with Drug-Eluting and Bare Metal Stents

Probal Roy*, Ron Waksman

*Corresponding author for this work

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

    Original languageEnglish
    Title of host publicationPharmacology in the Catheterization Laboratory
    PublisherWiley-Blackwell, Wiley
    Pages31-40
    Number of pages10
    ISBN (Print)9781405157049
    DOIs
    Publication statusPublished - 30 Oct 2009

    Keywords

    • Antiplatelet therapy
    • Antiplatelet therapy in BMS era
    • Antiplatelet therapy in DES era
    • Coronary artery disease (CAD)
    • Drug-eluting stents (DES)
    • Optimal antiplatelet therapy with drug-eluting and bare metal stents
    • Percutaneous coronary intervention (PCI)
    • Sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES)
    • Stent implantation-focal treatment of systemic process
    • Sustained dual antiplatelet therapy on cardiac outcomes in CURE, PCI-CURE, and CREDO

    Cite this